2-Pyrazoline, 4-ethyl-1-methyl- | 22581-42-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑啉类
• 英文名称: 2-Pyrazoline, 4-ethyl-1-methyl-
• 英文别名: 4-ethyl-2-methyl-3,4-dihydropyrazole
• CAS: 22581-42-6
• 化学式: C₆H₁₂N₂
• 分子量: 112.17
• InChiKey: DHEAFGCWGYSLFH-UHFFFAOYSA-N

物化性质

• 沸点：
  149.4±23.0 °C(Predicted)
• 密度：
  0.98±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  15.6
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• SYNTHESIS OF SUBSTITUTED PYRAZOLINE CARBOXAMIDINE DERIVATIVES
  申请人：van Loevezijn Arnold

  公开号：US20130060041A1

  公开（公告）日：2013-03-07

  This invention relates to organic chemistry, in particular to processes for the preparation of pyrazoline carboxamidine derivatives of formula (I), known as potent 5-HT6 antagonists. The invention also relates to novel intermediates of these compounds. wherein the symbols have the meanings given in the description.

  本发明涉及有机化学，特别是关于制备式(I)的吡唑啉羧酰胺衍生物的过程，这些衍生物被称为有效的5-HT6受体拮抗剂。本发明还涉及这些化合物的新型中间体。其中符号的含义如描述所示。
• CONDENSED CYCLIC COMPOUND HAVING DOPAMINE D3 RECEPTOR ANTAGONISM
  申请人：Shionogi & Co., Ltd

  公开号：EP3744721A1

  公开（公告）日：2020-12-02

  Novel compounds having a D3 receptor antagonistic effect are provided. The compound represented by Formula (IA)': wherein A is S or O; R1a is substituted or unsubstituted alkyloxy or the like, R2a to R2d are each independently hydrogen atoms or the like, ring B is a 4- to 8-membered non-aromatic carbocycle or the like, R3 is each independently halogen or the like, r is an integer of 0 to 4, R4 is substituted or unsubstituted aromatic heterocyclyl or the like, or a pharmaceutically acceptable salt thereof.

  提供了具有 D3 受体拮抗作用的新型化合物。 由式（IA）'代表的化合物： 其中 A 是 S 或 O；R1a 是取代或未取代的烷氧基或类似物；R2a 至 R2d 各自独立地是氢原子或类似物；环 B 是 4 至 8 元非芳族碳环或类似物；R3 各自独立地是卤素或类似物；r 是 0 至 4 的整数；R4 是取代或未取代的芳族杂环或类似物、 或其药学上可接受的盐。
• SOLUBLE GUANYLATE CYCLASE ACTIVATORS
  申请人：Schmidt Darby

  公开号：US20130012511A1

  公开（公告）日：2013-01-10

  The invention relates to compounds having the structure of Formula (I) and pharmaceutically acceptable salts thereof, which are soluble guanylate cyclase activators. The compounds are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.
• US7728018B2
  申请人：——

  公开号：US7728018B2

  公开（公告）日：2010-06-01
• US9422244B2
  申请人：——

  公开号：US9422244B2

  公开（公告）日：2016-08-23